News
Hosted on MSN7mon
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong - MSNArrowhead is also eligible for up to $10 billion in potential milestones and low double-digit royalties. Needham lowered Sarepta’s price target to $202 from $205, maintaining a ‘Buy’ rating.
Hosted on MSN4mon
Arrowhead and Sarepta close $500 million licensing deal - MSNArrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share.
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...
Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...
Sarepta will also send Arrowhead $50 million a year for the next five years. Under the deal, Arrowhead will complete the Phase 1/2 trials underway for the four clinical-stage drugs, ...
Sarepta’s new clinical programs from Arrowhead aim to treat facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, idiopathic pulmonary fibrosis and spinocerebellar ataxia 2.
Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...
In addition, Sarepta and Arrowhead have entered into a discovery collaboration for up to six additional muscle, cardiac, and/or CNS targets, using Arrowhead’s novel delivery technologies. As part of ...
Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ...
Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...
Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...
Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share. Over the next five years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results